Table 1. Participant clinical features by hallucinations.
| Hallucinations | No hallucinations | p | ||||
| n | 28 | 83 | ||||
| Age (Y) | mean (SD) | 73.1 | (7.1) | 68.6 | (7.7) | 0.006 |
| Sex (Male) | n (%) | 13 | (46%) | 33 | (40%) | 0.7 |
| Duration of PD (Y) | mean (SD) | 9.0 | (4.2) | 7.7 | (4.6) | 0.15 |
| history of psychosis | Yes, n (%) | 11 | (52%) | 19 | (24%) | 0.02 |
| No, n (%) | 10 | (48%) | 60 | (76%) | ||
| Initial symptoms | Tremor, n (%) | 11 | (46%) | 36 | (43%) | 1.00 |
| Others, n (%) | 13 | (54%) | 47 | (57%) | ||
| modified H-Y | 4–5, n (%) | 14 | (50%) | 26 | (31%) | 0.11 |
| 1–3, n (%) | 14 | (50%) | 57 | (69%) | ||
| UPDRS-3 | median (IQR) | 27 | (20–39) | 20 | (14–26) | 0.002 |
| MMSE | median (IQR) | 26 | (24–29) | 29 | (26–30) | 0.004 |
| PPQ-A (sleep disorder) | median (IQR) | 1 | (0–2) | 0 | (0–1) | 0.046 |
| L-Dopa dose (mg/day) | mean (SD) | 493.8 | (184.7) | 414.8 | (173.9) | 0.09 |
| DA agonist (LDED mg/day) | median (IQR) | 25.1 | (0–134) | 100 | (0–168) | 0.06 |
| selegiline (mg/day) | median (IQR) | 0.0 | (0.0–3.8) | 0.0 | (0.0–5.0) | 0.50 |
| amantadine (mg/day) | median (range) | 0.0 | (0.0–50) | 0.0 | (0.0–0.0) | 0.23 |
| plasma CRP (mg/L) | median (IQR) | 0.8 | (0.3–1.8) | 0.4 | (0.1–0.8) | 0.003 |
| white blood cell count | mean (SD) | 5,568 | (1,166) | 5,233 | (1,419) | 0.26 |
| albumin (mg/dL) | mean (SD) | 4.0 | (0.3) | 4.1 | (0.3) | 0.09 |
Statistical analysis was performed as follows; t-test for age, duration, UPDRS–3, MMSE, Dopa dose, white blood cell count, and albumin. Chi-square test for modified H-Y stage. Mann-Whitney U test for PPQ-A score, DA agonist, selegiline, amantadine and plasma CRP because of non-Gaussian distributions.